Yahoo Finance Results
- Zacks via Yahoo FinanceNov 06 22:55 PM
Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. Rigel, which belongs to the Zacks ...
- Benzinga via Yahoo FinanceNov 04 18:35 PM
(after the market close) Neurocrine Biosciences, Inc. NASDAQ: NBIX) (after the market close) Dynavax Technologies Corporation (NASDAQ: DVAX) (after the market close) PTC Therapeutics, ...
- Thomson Reuters StreetEvents via Yahoo FinanceNov 07 4:25 AM
Q3 2018 Rigel Pharmaceuticals Inc Earnings Call South San Francisco Nov 7, 2018 (Thomson StreetEvents) -- Edited Transcript of Rigel Pharmaceuticals Inc ...
- Associated Press via Yahoo FinanceNov 06 21:51 PM
Rigel Pharmaceuticals Inc. RIGL) on Tuesday reported a loss of $23.8 million in its third quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 14 cents.
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos OfferingBenzinga via Yahoo FinanceNov 06 12:04 PM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 5) Allakos Inc (NASDAQ: ALLK ) Allogene Therapeutics Inc ...
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.
SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2018 financial results after market close on Tuesday, November 6 , 2018.
10 September 2018 Here's Why Rigel Pharmaceuticals, Inc. Jumped Over 20% in August 31 August 2018 New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
FDA approval of Rigel's Tavalisse is a significant milestone for the company. Rigel is more than just a one trick pony. The market's reaction to Rigel's announced secondary offering provides a ...
The company only recorded sales of $1.8 million for Tavalisse in the second quarter, but the launch took place on May 29, so the quarterly revenue basically represented a month of sales with a ...
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases.